Basal Cell and Squamous Cell Skin Cancers

Miller, Stanley J.; Alam, Murad; Andersen, James S.; Berg, Daniel; Bichakjian, Christopher K.; Bowen, Glen M.; Cheney, Richard; Glass, L. Frank; Grekin, Roy C.; Kessinger, Anne; Lee, Nancy Y.; Liégeois, Nanette J.; Lydiatt, Daniel D.; Michalski, Jeff M.; Morrison, William H.; Nehal, Kishwer S.; Nelson, Kelly C.; Nghiem, Paul; Olencki, Thomas; Perlis, Clifford S.; Rosenberg, Elizabeth; Shaha, Ashok R.; Urist, Marshall M.; Wang, Linda C.; Zic, John A.

doi:10.6004/jnccn.2010.0062

Cited by 114 publications

(101 citation statements)

References 155 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surgical therapy for NMSC should be performed according to current guidelines, and clear margins on histologic examination should be obtained (16). Radiation therapy is helpful if surgical excision is not curative (17).…”

mentioning

confidence: 99%

Management of Non-Melanoma Skin Cancer in Solid Organ Transplant Recipients

Specchio

Saraceno

Chimenti

et al. 2014

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Non-melanoma skin cancer (NMSC) is the most frequent cancer observed in solid organ transplant recipients (SOTR). Early diagnosis, patient education, and modification of immunosuppression are effective measures for reduction of NMSC incidence. Many risk factors have been identified, including age at transplantation, fair skin, type of immunosuppressive drugs, cumulative sun exposure, viral infections, and various genetic markers. Skin self-examination and photoprotection should be encouraged in all transplanted patients. Long-term skin surveillance, early diagnosis and aggressive treatment of any suspicious lesion, reduction of immunosuppressive therapy, and conversion to mammalian target-of-rapamycin (m-TOR) inhibitors can be also effective measures for reduction of NMSC incidence.

show abstract

mentioning

confidence: 99%

Management of Non-Melanoma Skin Cancer in Solid Organ Transplant Recipients

Specchio

Saraceno

Chimenti

et al. 2014

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…In transplant recipients, cSCC develops 10-30 years earlier than in immunocompetent hosts [10]. For comprehensive details on the clinical and histologic parameters associated with MCC, cSCC, and BCC, the reader is referred to excellent article reviews [10,[17][18][19][20]. In the present review, we describe options that are commonly used in our cutaneous oncology practice.…”

Section: Clinical and Histological Presentationmentioning

confidence: 95%

“…Five percent cream and solution formulations have been approved by the FDA in the United States for the treatment of sBCC when conventional methods are impractical. Because the cure rate is considered lower than surgery or radiation therapy, the National Comprehensive Cancer Network (NCCN) guidelines reserve this therapy in patients with low-risk sBCC where surgery or radiation is contraindicated or impractical [20]. Because the percutaneous penetration of 5-FU is variable and limited [29][30][31], its use is recommended only for sBCC and not other histologic types of BCC.…”

Section: -Fluorouracilmentioning

confidence: 99%

Skin Cancer and the Solid Organ Transplant Recipient

Patel

Liégeois

2008

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Organ transplant recipients (OTRs) are living longer in setting of improved medical immunosuppression. The most common late post-transplant complication includes a variety of malignant and premalignant cutaneous tumors. Aggressive skin cancers are common in this population. Clinical and pathologic correlation is essential in choosing the appropriate treatment for the various subtypes of skin cancer in OTR. Approaches include risk assessment for other skin tumors, treatment of malignancy, and prevention. Few prospective or retrospective studies with multivariate analysis exist and therefore opinion largely dominates treatment recommendations. Treatment aims: (i) The mainstay of treatment focuses on total removal (excision) or mechanical destruction of the tumor. In the appropriate clinical scenario, a skin cancer should be removed or treated fully. (ii) Treatment modality is dependant upon low- vs high-risk tumors and tumor type. (iii) Utilize excision with margin control, either by permanent or frozen (Mohs) technique, for large tumors and tumors in high-risk sites. (iv) New treatment modalities include immune modulators, topical photodynamic therapy, and drugs targeting genetic defects. (v) Education on skin cancer prevention should target all the age groups.

show abstract

“…Radiotherapy may be best applied to patients over age 60 [25]. Younger age is a relative contraindication for RT because of increased risk of additional NMSC lesions in the radiation treatment field [26,27]; however, RT remains a viable treatment option for these patients [7,9].…”

Section: Indications For Radiotherapy In Nmscmentioning

confidence: 98%

Treatment of Non-Melanomatous Skin Cancer with Radiotherapy

et al. 2015

View full text Add to dashboard Cite

Non-melanomatous skin cancer (NMSC) is the leading cause of cancer in the United States. Treatment with surgical excision is considered the gold standard, but radiotherapy is an excellent alternative to surgical excision. Radiotherapy for NMSC takes many forms including a variety of external beam treatments as well as brachytherapy. Radiotherapy is indicated in a broad range of patients and is particularly useful in elderly patients who are poor surgical candidates or prefer not to have surgery. Radiotherapy is also employed in certain cases of recurrence and perineural invasion and when margin control is a concern. In addition to discussing standard techniques and indications for radiotherapy, this article will review specific considerations for radiotherapy in the treatment of basal cell carcinoma and squamous cell carcinoma. Finally, the article will examine new developments in the treatment of NMSC with radiotherapy including electronic brachytherapy and Helical TomoTherapy.

show abstract

Basal Cell and Squamous Cell Skin Cancers

Cited by 114 publications

References 155 publications

Management of Non-Melanoma Skin Cancer in Solid Organ Transplant Recipients

Management of Non-Melanoma Skin Cancer in Solid Organ Transplant Recipients

Skin Cancer and the Solid Organ Transplant Recipient

Treatment of Non-Melanomatous Skin Cancer with Radiotherapy

Contact Info

Product

Resources

About